Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)

• Главные авторы: Wiktoria (Автор), Anna Greguła (Автор), Karol Stachyrak (Автор), Dawid Mika (Автор), Aleksandra Kłos (Автор), Kamila Turek (Автор), Maciej Lambach (Автор), Mateusz Pawlicki (Автор), Aleksandra Mazurek (Автор), Bartosz Mazur (Автор)
• Формат: ‌
• Опубликовано: Kazimierz Wielki University, 2024-02-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Introduction Viloxazine is an antidepressant medication classified as an SNRI (serotonin and norepinephrine reuptake inhibitor). In April 2021, it received FDA approval in the United States for the treatment of ADHD in children aged 6 to 17. Subsequently, in May 2022, it was also approved for the tr...